Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 12345 Views
-
Last post by NHE
-
- 0 Replies
- 1180 Views
-
Last post by NHE
-
- 0 Replies
- 1951 Views
-
Last post by frodo
-
- 0 Replies
- 1250 Views
-
Last post by frodo
-
- 0 Replies
- 2114 Views
-
Last post by NHE
-
- 0 Replies
- 1699 Views
-
Last post by frodo
-
- 0 Replies
- 1322 Views
-
Last post by NHE
-
- 1 Replies
- 1795 Views
-
Last post by frodo
-
- 0 Replies
- 2547 Views
-
Last post by NHE